Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in (Q57243499)
scholarly article by Kim Fox et al published November 2006 in American Heart Journal
Language:
Current Data About Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in
(P31) (Q13442814)

(P50) (Q16027739)
(P1932) Philippe Gabriel Steg
(P1545) 4

(Q48860774)
(P1545) 3
(P1932) Michal Tendera

(P304) 860-866

(P407) (Q1860)

(P433) 5

(P478) 152

(P577) +2006-11-00T00:00:00Z

(P921) (Q181600)

(Q496359)
(P887)

(Q269829)
(P887)

(Q108853737)
(P887)

(Q844935)
(P887)

(P1433) (Q2227156)

(P1476) "Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in" (language: en)

(P2093) Kim Fox
(P1545) 1

Roberto Ferrari
(P1545) 2

Ian Ford
(P1545) 5

other details
description scholarly article by Kim Fox et al published November 2006 in American Heart Journal

External Links
(P356) 10.1016/J.AHJ.2006.01.013
(P698) 17070146